For the first time in Nepal, genetic testing, also known as "Gene Sequencing," related to breast cancer (BRCA1 and BRCA2) has ...

OlympiA 是一项前瞻性多国多中心双盲临床研究，旨在探究 HER2-、携带 gBRCA 突变且具有高复发风险的早期乳腺癌患者的治疗效果。入组患者在完成（新）辅助治疗及局部治疗后，按 1:1 比例随机分配接受为期 1 ...

2025年1月2日——阿斯利康与默沙东联合宣布其PARP抑制剂利普卓®（英文商品名：Lynparza，通用名：奥拉帕利）在华获批用于接受过新辅助或辅助化疗的携带有害或疑似有害胚系BRCA突变（gBRCAm）、人表皮生长因子受体2（HER2）阴性早期高 ...

By filling the gaps on testing and giving people with harmful mutations better ways to reduce their risk, BRCA1 and BRCA2 testing could become a model for how genetic tests for other cancer risk ...

近期，一位网红“咖啡”公开分享了自己因基因缺陷导致患癌的经历，并在经历了九次无效的化疗后决定放弃治疗。这一情况引发了公众对基因与癌症关系的关注。通过对基因缺陷引发癌症的病理机制、早期筛查的重要性以及健康管理的探讨，可以帮助大家更好地理解这类疾病，提高 ...

Anyone looking into genetic testing for cancer should seek support from a genetic counselor; you don't know what kind of ...

Australians with prostate and breast cancer now have affordable access to affordable new and expanded medicines under the ...

It's been long known that women with BRCA1 and BRCA2 gene mutations are at higher risk for breast and ovarian cancer. Advertisement More than 60% of women who inherit a BRCA mutation will develop ...

Our case report has shown the impressive results of PARPi therapy used in a patient with a somatic BRCA2 mutation. To our knowledge, this is the first case demonstrating the utility of niraparib in ...

The Australian government announces Olaparib now available on the PBS for HER2-negative metastatic breast cancer patients with mutated BRCA1 or BRCA2 gene.

SAN ANTONIO – Patients with germline BRCA mutations who were diagnosed with breast cancer at or before age 40 and who underwent a bilateral risk-reducing mastectomy (RRM) and/or a risk-reducing ...